Evidence of the Efficacy of Flurbiprofen 8.75 mg Lozenges for Patients Receiving Antibiotics for Laboratory-Confirmed Streptococcal Pharyngitis.

Autor:	Schachtel B; Schachtel Research Associates, Inc, Jupiter, FL, USA.; Yale School of Public Health, New Haven, CT, USA., Shephard A; Reckitt Benckiser Healthcare International Ltd, Slough, United Kingdom., Schachtel E; Schachtel Research Associates, Inc, Jupiter, FL, USA., Shea T; Reckitt Benckiser Health LLC, NJ, USA., Smith A; Reckitt Benckiser Healthcare Ltd, Hull, United Kingdom., Tselenti E; Reckitt Benckiser Healthcare Ltd, Hull, United Kingdom.
Jazyk:	angličtina
Zdroj:	Ear, nose, & throat journal [Ear Nose Throat J] 2023 Dec; Vol. 102 (12), pp. NP609-NP617. Date of Electronic Publication: 2021 Jul 14.
DOI:	10.1177/01455613211025754
Abstrakt:	Objectives: To determine the efficacy of flurbiprofen 8.75 mg lozenges for patients with laboratory-confirmed streptococcal pharyngitis both before and concomitant with antibiotics. Methods: This post hoc analysis comprised adult participants from 2 earlier randomized, double-blind, placebo-controlled studies evaluating the analgesic efficacy of flurbiprofen 8.75 mg lozenges in acute pharyngitis. Throat swabs were obtained to diagnose streptococcal infection. Prior to and 2 hours after each dose of study medication (flurbiprofen or placebo lozenges), patients rated 3 symptoms of acute pharyngitis (sore throat pain, difficulty swallowing, and swollen throat) using visual analogue scales. Appropriate antibiotic treatment was initiated when culture results were reported. Mean changes in each pharyngeal symptom were compared over the immediate 24 hours before and during the initial 24 hours of antibiotic treatment. Results: Twenty-four patients provided both preantibiotic and concomitant antibiotic efficacy outcomes. Relief of throat pain was 93% greater in the flurbiprofen group than in the placebo group before antibiotic coadministration and 84% greater than placebo during antibiotic administration (both P < .05). Relief of difficulty swallowing was 71% greater in the flurbiprofen group than in the placebo before antibiotic administration (P = .16) and 107% greater during concomitant antibiotic administration (P = .04). Relief of the sensation of throat swelling was 295% greater with flurbiprofen than placebo before antibiotic administration (P = .008) and 70% greater during concomitant antibiotic administration (P = .06). For placebo-treated patients, relief from throat pain and difficulty swallowing were similar before and during antibiotic treatment (P > .05), indicating no benefit with antibiotic administration for these symptoms. No treatment-related discontinuations or serious adverse events were reported. Conclusions: Irrespective of antibiotic use, flurbiprofen 8.75 mg lozenges provide well-tolerated, effective relief of pharyngeal symptoms in patients with streptococcal infection. In the 24 hours after administration, antibiotics provide no relief of throat pain or difficulty swallowing beyond the topical demulcent effects of placebo lozenges. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Tim Shea, Adam Smith, and Adrian Shephard are employees of Reckitt Benckiser. Evi Tselenti was an employee of Reckitt Benckiser when this manuscript was being prepared. Bernard Schachtel and Emily Schachtel (at Schachtel Research Company) received a research grant from Reckitt Benckiser to design and conduct the studies.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu